KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' Net Income towards Common Stockholders fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
  • Aquestive Therapeutics' Net Income towards Common Stockholders amounted to -$15.4 million in Q3 2025, which was down 14.01% from -$13.5 million recorded in Q2 2025.
  • Aquestive Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $8.1 million during Q1 2023, with a 5-year trough of -$28.9 million in Q4 2021.
  • Over the past 3 years, Aquestive Therapeutics' median Net Income towards Common Stockholders value was -$11.5 million (recorded in 2024), while the average stood at -$9.4 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Net Income towards Common Stockholders soared by 161.03% in 2023 and then crashed by 465.55% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then skyrocketed by 34.33% to -$8.1 million in 2023, then plummeted by 110.27% to -$17.1 million in 2024, then plummeted by 34.21% to -$15.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$15.4 million for Q3 2025, versus -$13.5 million for Q2 2025 and -$22.9 million for Q1 2025.